TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15733521
Drug: Isosmotic electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosmotic electrolyte solution
Study: 7288563
Drug: Misattribution treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misattribution treatment (high-frequency noise)
Study: 28763243
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI 50/12.5 mcg
Study: 28763243
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI 100/12.5 mcg
Study: 28763243
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 50 mcg
Study: 28763243
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 100 mcg
Study: 22017530
Drug: Y1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Y1 antagonist (AR-H040922) during atenolol
Study: 22017530
Drug: Y1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Y1 antagonist (AR-H040922) during metoprolol
Study: 21111318
Drug: Gas-forced infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gas-forced infusion (air pump)
Study: 21111318
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gas-forced infusion)
Study: 16802774
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 200 microg daily
Study: 12594897
Drug: Acylaminopenicillin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acylaminopenicillin-based therapy
Study: 12594897
Drug: Cephalosporin-based antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin-based antibiotic therapy
Study: 6536768
Drug: Grief group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grief group therapy
Study: 24762259
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet (6-months treatment)
Study: 10852048
Drug: New concentrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New concentrated inactivated leptospirosis vaccine (0.5 ml, single injection)
Study: 10852048
Drug: Existing commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Existing commercial vaccine (2.0 ml and 2.5 ml, two injections)
Study: 1710591
Drug: Hydroxyethyl-starch (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl-starch (250 ml daily) + Pentoxifylline (oral: 1200 mg/day; i.v.: 300 mg/day)
Study: 1710591
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hemodilution or rheological therapy)
Study: 29155035
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.25% bupivacaine (treatment group)
Study: 29155035
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL normal saline solution (control group)
Study: 23102189
Drug: Fluticasone/formoterol 250/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol 250/10 μg twice daily
Study: 23102189
Drug: Budesonide/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 400/12 μg twice daily
Study: 10320241
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (HCCs)
Study: 1679626
Drug: Massed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed treatment condition (shorter intersession intervals)
Study: 1679626
Drug: Spaced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced treatment condition (longer intersession intervals)
Study: 6627195
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation at all
Study: 28128751
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (NaCl)
Study: 22113068
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom daily for 1 week
Study: 22113068
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily diet without WBM (control group)
Study: 22113068
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom
Study: 19945492
Drug: Chickpea supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chickpea supplemented diet (average 104 g/day)
Study: 17494881
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and steroids (prednisolone) for 6 months
Study: 17494881
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment (control group)
Study: 16327614
Drug: Preoperative single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative single intravenous dose of antibiotics
Study: 16327614
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen with preoperative single-shot antibiotics plus a postoperative 7-day course of oral antibiotics
Study: 11872885
Drug: Weight-based heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based heparin nomogram
Study: 9495223
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg single oral dose
Study: 2497168
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg, sustained-release, Theo-Dur)
Study: 1092420
Drug: Intermittent positive-pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent positive-pressure ventilation (I.P.P.V.) of 10 mg of salbutamol
Study: 1092420
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose (200 mug) from a pressurized canister
Study: 447817
Drug: Melatonin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (250 mg every 8 h over a period of 40 h)
Study: 31425700
Drug: 13 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg/day total MXans
Study: 31425700
Drug: 27 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 mg/day total MXans
Study: 30136102
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 200 mg in the morning, 100 mg in the evening
Study: 30136102
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of pregabalin 150 mg and tramadol ER 200 mg in the morning, and pregabalin 150 mg and tramadol ER 100 mg in the evening
Study: 26728611
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg once daily for nine days)
Study: 26728611
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg twice daily for nine days)
Study: 25141536
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise with self-manual therapy
Study: 25141536
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise without self-manual therapy
Study: 17644512
Drug: Anti-anginal drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anginal drug therapy in addition to risk factor control (MED)
Study: 17644512
Drug: Anti-anginal drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anginal drug therapy (MED)
Study: 16227030
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g amino acids (AA)/(kg.d) from birth onward
Study: 16227030
Drug: Glucose only
Normalized name: Glucose only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose only during the first day with a stepwise increase in AA intake to 2.4 g AA/(kg.d) on day 3
Study: 10086669
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg q.i.d. for 4 days
Study: 7648705
Drug: cA2, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2, a chimaeric anti-TNF-α monoclonal antibody (MoAb)
Study: 31955940
Drug: Ultralong, 6.35-cm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Study: 31955940
Drug: Standard long,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long, 4.78-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Study: 30845037
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prophylactic antibiotics (n = 4,523)
Study: 24386952
Drug: Concurrent cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent cetuximab and pemetrexed (Arm B)
Study: 24386952
Drug: Cetuximab therapy
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab therapy
Study: 7578729
Drug: Drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10)
Study: 7578729
Drug: Drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13)
Study: 7578729
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy with L-AmB alone (3 mg/kg daily for 10 days)
Study: 7578729
Drug: Regimen 3
Normalized name: Bayer Aspirin Regimen 325mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7)
Study: 7578729
Drug: Optimal regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal regimen of L-AmB
Study: 2339368
Drug: F XIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: F XIII concentrate administered within 6 hours after delivery
Study: 565418
Drug: Isotonic amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic amino acid infusions
Study: 565418
Drug: Preoperative keto-adaptation
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative keto-adaptation by a carbohydrate-free, oral protein diet
Study: 565418
Drug: Postoperative amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative amino acid infusions only
Study: 565418
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent dextrose infusions
Study: 29315160
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (1200 IU)
Study: 21912983
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (2 Hz/32.4 mJ/5.9 J/cm(2))
Study: 21912983
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser treatment (0.25 W/4.4 J/cm(2))
Study: 21912983
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser treatment (0.50 W/8.9 J/cm(2))
Study: 20523083
Drug: Platinum-based first-line
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based first-line chemotherapy
Study: 20523083
Drug: Non-platinum-based first-line
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based first-line chemotherapy
Study: 20523083
Drug: Platinum-based second-line
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based second-line chemotherapy
Study: 20523083
Drug: Non-platinum-containing second-line
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-containing second-line chemotherapy
Study: 16188050
Drug: Aspirin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-sensitive group
Study: 11813818
Drug: Quantitative CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative CT in the evaluation of patients with emphysema for surgery and drug therapy
Study: 7554633
Drug: Enoxaparin 10
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 10 mg once daily
Study: 7554633
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose unfractionated heparin (5000 IU 3 times daily or 7500 IU twice daily)
Study: 7554633
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg twice daily, 40 mg once daily, 10 mg once daily)
Study: 373841
Drug: Cephaloridine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephaloridine (3 doses, continued for 12 hours post-surgery)
Study: 28639118
Drug: T0001 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T0001 (10, 20, 35, 50, 65, or 75 mg)
Study: 23725215
Drug: Long-acting beta-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta-agonists
Study: 12755836
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (300 mg nizatidine)
Study: 12755836
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (30 mg lansoprazole)
Study: 12755836
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (overall efficacy from 12 studies)
Study: 12755836
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (overall efficacy from 12 studies)
Study: 12755836
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (clarithromycin-containing regimens)
Study: 12755836
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (non-clarithromycin-containing trials)
Study: 9071052
Drug: Caffeine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine, dosage and duration not specified
Study: 7529464
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 million units loading dose, 2 million units added to the CPB prime, and 500,000 units/hr maintenance infusion)
Study: 3164442
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin (ivGG) infusion
Study: 23672818
Drug: Atomoxetine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine once daily (n = 32)
Study: 18972727
Drug: Scalp-acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp-acupuncture plus exercise therapy
Study: 11008326
Drug: L-Tryptophan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Tryptophan (500 mg)
Study: 1673628
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.075 mg once daily)
Study: 31519130
Drug: Hyperfractionated, Accelerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated, Accelerated Radiotherapy (HART) prescribed as 76 Gy in 56 fractions, 10 fractions weekly; no chemotherapy
Study: 21551510
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day
Study: 15195061
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C applied to the intact tympanic membrane
Study: 7859799
Drug: Lifibrol 150
Normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol 150 mg/day
Study: 7859799
Drug: Lifibrol 300
Normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol 300 mg/day
Study: 7859799
Drug: Lifibrol 450
Normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol 450 mg/day
Study: 7859799
Drug: Lifibrol 600
Normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol 600 mg/day
Study: 7859799
Drug: Lifibrol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifibrol (high baseline levels > 30 mg.dl-1)
Study: 31600432
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Treatment for Depression (BATD), 12 sessions
Study: 21154218
Drug: Ketamine (0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.23 mg/kg bolus followed by 0.64 mg/kg/h)
Study: 10696840
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment for large adenomas and early colorectal cancer
Study: 26771854
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for recurrent vestibular schwannoma (Group A: previously operated on and received postoperative radiosurgery; Group B: previously operated on but did not receive postoperative radiosurgery)
Study: 26771854
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for recurrent vestibular schwannoma (Group A and B)
Study: 26771854
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for recurrent vestibular schwannoma
Study: 23214247
Drug: CCS combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCS combined with NBT and YB capsules
Study: 20164307
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 104.9 mg . kg(‐1) . d(‐1)
Study: 20164307
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 117.6 mg . kg(‐1) . d(‐1)
Study: 17515572
Drug: Trastuzumab 4
Normalized name: TRASTUZUMAB 440MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m2 every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery
Study: 17515572
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (docetaxel and carboplatin)
Study: 10458713
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment for 6 weeks
Study: 2218849
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (control of risk factors for stroke including hypertension, diabetes, and hyperlipidemia, and antiplatelet aggregant medication)
Study: 2218849
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment plus superficial temporal‐to‐middle cerebral artery bypass
Study: 2218849
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment plus carotid endarterectomy
Study: 31087723
Drug: Disulfiram treatment
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment for 12 weeks
Study: 16454830
Drug: Intranasal mupirocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mupirocin, arbekacin inhalation, and oral sulfamethoxazole/trimethoprim (Group C)
Study: 8375242
Drug: Ala 20
Normalized name: emtricitab/rilpiviri/tenof ala 200 mg-25 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ala 20 g orally
Study: 8375242
Drug: Ala 40
Normalized name: Nucala 40 MG in 0.4 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ala 40 g orally
Study: 8375242
Drug: Terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 2.5 mg orally
Study: 8375242
Drug: Terbutaline 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 5.0 mg orally
Study: 8375242
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline 0.25 mg
Study: 8375242
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 0.4 mg
Study: 28857147
Drug: Ambrisentan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (5 mg)
Study: 20420792
Drug: Prestodol (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestodol (test formulation)
Study: 1769635
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 x 20 mg retard)
Study: 1769635
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Clonidine and Nifedipine (C/N)
Study: 31479003
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost for 5 min
Study: 28794410
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, and oral hygiene instruction
Study: 28794410
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene care programme (AOHCP)
Study: 28794410
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene care programme (COHCP)
Study: 23126237
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (160/4.5 μg 1 inhalation twice daily plus as-needed budesonide/formoterol 160/4.5 μg)
Study: 23126237
Drug: Budesonide/formoterol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol plus terbutaline (160/4.5 μg 1 inhalation twice daily plus as-needed terbutaline 0.4 mg)